The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non–small-cell lung cancer (ES-NSCLC).
 
Jennifer Bordeaux
Employment - Navigate BioPharma
 
Naveen Dakappagari
Employment - Navigate BioPharma
Stock and Other Ownership Interests - Biogen; Novartis
Patents, Royalties, Other Intellectual Property - Novartis
 
Nathan A. Pennell
Consulting or Advisory Role - AstraZeneca; Lilly; Regeneron
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech (Inst); Merck; Newlink Genetics (Inst); Pfizer (Inst)
 
James Stevenson
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
 
Monica Khunger
No Relationships to Disclose
 
Christine Vaupel
Employment - Navigate BioPharma
Stock and Other Ownership Interests - Novartis
 
Kurt A. Schalper
Honoraria - Takeda
Consulting or Advisory Role - Celgene; Shattuck Labs
Research Funding - Moderna Therapeutics; Navigate BioPharma; Onkaido Therapeutics; Pierre Fabre; Surface Oncology; Takeda; Tesaro; Vasculox
 
David L. Rimm
Stock and Other Ownership Interests - Pixel Gear
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Cell Signaling Technology; Genentech
Consulting or Advisory Role - Agendia; AstraZeneca; Bethyl Laboratories; Biocept; Bristol-Myers Squibb; Clearsight; Five Prime Therapeutics; Genoptix; Merck; Optra SCAN; Perkin Elmer; Ultivue
Research Funding - AstraZeneca/MedImmune (Inst); Cepheid; Gilead Sciences; NextCure (Inst); OncoPlex Diagnostics; Perkin Elmer; Pierre Fabre (Inst)
Patents, Royalties, Other Intellectual Property - Quantitative Immunofluorescence (AQUA) (Inst); Rarecyte Circulating tumor cells
Travel, Accommodations, Expenses - Genentech; NextCure; Ventana Medical Systems
 
Vamsidhar Velcheti
Honoraria - Bristol-Myers Squibb; Foundation Medicine; Genentech/Roche; Merck; Novartis
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Clovis Oncology; Foundation Medicine; Genentech; Genoptix; Merck; Takeda
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); Trovagene (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Eisai; Foundation Medicine; Merck